scholarly journals Changes in HMO Concentrations throughout Lactation: Influencing Factors, Health Effects and Opportunities

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2272
Author(s):  
Caroline Thum ◽  
Clare Rosemary Wall ◽  
Gisela Adrienne Weiss ◽  
Wendan Wang ◽  
Ignatius Man-Yau Szeto ◽  
...  

Human milk oligosaccharides (HMOs) are important functional biomolecules in human breast milk. Understanding the factors influencing differences in HMO composition and changes in their concentration over lactation can help to design feeding strategies that are well-adapted to infant’s needs. This review summarises the total and individual concentration of HMOs from data published from 1999 to 2019. Studies show that the HMO concentrations are highest in colostrum (average 9–22 g/L), followed by slightly lower concentrations in transitional milk (average 8–19 g/L), with a gradual decline in mature milk as lactation progresses, from 6–15 g/L in breast milk collected within one month of birth, to 4–6 g/L after 6 months. Significant differences in HMO composition have been described between countries. Different HMOs were shown to be predominant over the course of lactation, e.g., 3-fucosyllactose increased over lactation, whereas 2′-fucosyllactose decreased. Recent clinical studies on infant formula supplemented with 2′-fucosyllactose in combination with other oligosaccharides showed its limited beneficial effect on infant health.

2006 ◽  
Vol 139 (1) ◽  
pp. 107-117 ◽  
Author(s):  
Agus Sudaryanto ◽  
Tatsuya Kunisue ◽  
Natsuko Kajiwara ◽  
Hisato Iwata ◽  
Tussy A. Adibroto ◽  
...  

Nutrients ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 1643 ◽  
Author(s):  
Anna Ojo-Okunola ◽  
Mark Nicol ◽  
Elloise du Toit

It is well-known that, beyond nutritional components, human breast milk (HBM) contains a wide variety of non-nutritive bio-factors perfectly suited for the growing infant. In the pre-2000 era, HBM was considered sterile and devoid of micro-organisms. Though HBM was not included as part of the human microbiome project launched in 2007, great strides have been made in studying the bacterial diversity of HBM in both a healthy state and diseased state, and in understanding their role in infant health. HBM provides a vast array of beneficial micro-organisms that play a key role in colonizing the infant’s mucosal system, including that of the gut. They also have a role in priming the infant’s immune system and supporting its maturation. In this review, we provide an in-depth and updated insight into the immunomodulatory, metabolic, and anti-infective role of HBM bacteriome (bacterial community) and its effect on infant health. We also provide key information from the literature by exploring the possible origin of microbial communities in HBM, the bacterial diversity in this niche and the determinants influencing the HBM bacteriome. Lastly, we investigate the role of the HBM bacteriome in maternal infectious disease (human immunodeficiency virus (HIV) and mastitis)), and cancer. Key gaps in HBM bacterial research are also identified.


2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S899-S899
Author(s):  
Ryohei Izumita ◽  
Kazuki Kon ◽  
Yuta Aizawa ◽  
Kanako Watanabe ◽  
Akihiko Saitoh

Abstract Background Parechovirus-A3 (PeV-A3) is an emerging pathogen causing sepsis and meningoencephalitis in neonates and young infants. We previously reported that maternal antibodies against PeV-A3 are important to protect neonates and young infants from the infection. Recent studies showed that (1) breastfeeding had a protective effect against enterovirus, which is closely-related virus to PeV-A, and (2) human breast milk (HBM) neutralized enterovirus in vitro. Currently, no report is available related to the antiviral effect of HBM against PeV-A3. Methods HBM (colostrum, 3–5 days after childbirth; mature milk, 1 month after childbirth) and serum (within ± 1 week of child’s birthday) samples were obtained from mothers at obstetrics clinic in Niigata, Japan. Neutralizing antibody titers (NATs) against PeV-A3 were measured using the Vero cells. Results The anti-PeV-A3 NATs of colostrum (n = 32) ranged from 1:8 to 1:2048, those ≥1:32 was 59% (19/32). Whereas, the anti-PeV-A3 NATs of mature milk ranged from 1:8 to 1:96. and those ≥1:32 was 20% (2/20) (P < 0.001). The median NATs anti-PeV-A3 was higher in colostrum (1:32) compared with mature milk (1:8) (P < 0.001). There was a strong positive correlation between the NATs of colostrum and serum (r = 0.604, P < 0.001, Figure). Conclusion This study showed that HBM had high NATs against PeV-A3, which was correlated with serum NATs. Further studies are necessary to investigate which components of HBM has antiviral effects against PeV-A3. Disclosures All authors: No reported disclosures.


2012 ◽  
Vol 19 (04) ◽  
pp. 527-530
Author(s):  
SYED QAISER HUSAIN NAQVI ◽  
MOHAMMAD SHIRAZ KHAN ◽  
ALI AKBAR SIYAL ◽  
Mir Muhammad Sehto ◽  
Riaz Ahmed Qazi ◽  
...  

Objective: This study was aimed to see the significance of Lactoferrin in human breast milk among lactating mothers of healthyand sick babies. Place and duration: This study was conducted at pathology and paediatrics departments of Peoples University of Medical andHealth Sciences Nawabshah, Shaheed Benazirabad between Jan 2011 to Dec 2011. Design: Cross sectional study. Method: Lactoferrinlevels in breast milk of 356 mothers of healthy babies were estimated and similarly lactoferrin levels in breast milk of 318 lactating mothers ofsick babies were estimated & these results were analyzed. Results: the mean lactoferrin level in breast milk of 356 lactating mothers of healthybabies was 9.37 mg/ml and the mean lactoferrin level in breast milk of 318 mothers nursing sick babies was 3.73mg/ml. Conclusions: There isdecrease in lactoferrin levels of lactating mothers of sick babies in their mature milk, which could account for the susceptibility of their babies toinfection.


Author(s):  
Daniel O'Reilly ◽  
Denis Dorodnykh ◽  
Nina V Avdeenko ◽  
Nikita A Nekliudov ◽  
Johan Garssen ◽  
...  

ABSTRACT Human breast milk (HM) contains multiple bioactive substances determining its impact on children's health. Extracellular vesicles (EVs) are a heterogeneous group of secreted nanoparticles that are present in HM and may be partially responsible for its beneficial effects. The precise roles and content of EVs in HM remain largely unknown. To examine this, we performed a short narrative review on the literature focusing on HM EVs to contextualize the available data, followed by a scoping review of MEDLINE and Embase databases. We identified 424 nonduplicate citations with 19 original studies included. In this perspective, we summarize the evidence around HM EVs, highlight some theoretical considerations based on existing evidence, and provide an overview of some challenges associated with the complexity and heterogeneity of EV research. We consider how the existing data from HM studies conform to the minimal information for studies of EVs (MISEV) guidelines. Across the studies a variety of research methods were utilized involving both bench-based and translational methods, and a range of different EV contents were examined including RNA, proteins, and glycopeptides. We observed a variety of health outcomes in these studies, including allergy and atopy, necrotizing enterocolitis, and HIV. While some promising results have been demonstrated, the heterogeneity in outcomes of interest, methodological limitations, and relatively small number of studies in the field make comparison between studies or further translational work problematic. To date, no studies have examined normative values of HM EVs in a large, diverse population or with respect to potentially important influencing factors such as timing (hind- vs. foremilk), stage (colostrum vs. mature milk), and infant age (preterm vs. term), which makes extrapolation from bench or “basic” research impossible. Future research should focus on addressing the current inadequacies in the literature and utilize MISEV guidelines to inform study design.


2022 ◽  
Vol 17 (1) ◽  
Author(s):  
Takeshi Chiba ◽  
Aya Kooka ◽  
Kiyoko Kowatari ◽  
Megumi Yoshizawa ◽  
Naoko Chiba ◽  
...  

Abstract Background Milk-derived microRNAs (miRNAs), including hsa-miR-148a-3p (miR-148a) and hsa-miR-125b-5p (miR-125b), have been shown to be beneficial to the gastrointestinal function in infants. Here, we investigated their expression during lactation in humans and determined whether the infant formulae available in Japan contain these miRNAs. Methods Healthy Japanese women (n = 16) who gave birth vaginally or by cesarean section at the Teine Keijinkai Hospital between 1 September 2020, and 31 April 2021 were included in this study. Breast milk was collected by nurses on days 4 or 5 after delivery (hereinafter, transition milk) and on day 30 of postpartum (hereinafter, mature milk). The levels of miR-148a and miR-125b in breastmilk and six commercially available infant formulae were compared and evaluated using quantitative reverse transcription-polymerase chain reaction. Results In all participants, the miR-148a level in mature breastmilk was significantly lower than that in the transition milk. The changes in miR-125b expression during lactation showed similar trends to the changes in miR-148a expression. The miR-148a and miR-125b levels in all analyzed infant formulae were lower than 1/500th and 1/100th of those in mature breastmilk, respectively. Conclusions The levels of both miR-148a and miR-125b in human breast milk decreased on day 30 postpartum compared with those in the transition milk. Additionally, the expression of these miRNAs in infant formulae available in Japan was very low. Further studies with larger populations are required to understand precisely the lactational changes in the expression of miR148a and miR-125b in breast milk.


2009 ◽  
Vol 157 (6) ◽  
pp. 1924-1932 ◽  
Author(s):  
Govindan Malarvannan ◽  
Tatsuya Kunisue ◽  
Tomohiko Isobe ◽  
Agus Sudaryanto ◽  
Shin Takahashi ◽  
...  

2013 ◽  
Vol 110 (3) ◽  
pp. 524-528 ◽  
Author(s):  
J. Plaza-Zamora ◽  
M. Sabater-Molina ◽  
M. Rodríguez-Palmero ◽  
M. Rivero ◽  
V. Bosch ◽  
...  

Maternal milk is the first source of exogenous polyamines for the newborn. Polyamines modulate gut maturation in neonates, but no studies are available on polyamine concentration in human milk of preterm babies, even though they could be important for their immature gut. The present study aimed to determine polyamine concentration in human breast milk of mothers with preterm or term infants during the first month of lactation. Human milk samples were obtained during the first month of lactation from twenty-seven mothers with preterm babies and twelve mothers with babies born at term. The polyamine concentration in human milk was quantified by HPLC. During the first month of lactation, the total polyamine concentration was significantly higher in preterm milk than in term milk samples (7590 (sd 4990) v. 4660 (sd 4830) nmol/l, respectively (P =0·034)), as well as individual polyamine concentrations. Polyamine concentration in mature milk for preterm babies was significantly higher than that in mature milk for babies at term, and a similar trend was observed in colostrum and transition human milk. The spermidine/spermine ratio was higher in transition milk in preterm v. term samples, while in mature milk, the ratio was significantly lower in preterm than in term babies. In conclusion, the polyamine concentration was significantly higher in human milk for preterm than for term infants. This and the different spermidine/spermine ratios could influence the gut development of premature babies.


Sign in / Sign up

Export Citation Format

Share Document